Genetic determinants of HIV-1 infection and progression to AIDS: Susceptibility to HIV infection

Tissue Antigens

Volumn 73, Issue 4, 2009, Pages 289-301

  Kaur, G ^a   Mehra, N ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

AIDS; Chemokine receptors; Chemokines; Genes; HIV 1; Susceptibility; Virus entry

Indexed keywords

ANTIVIRUS AGENT; APOLIPOPROTEIN B; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; CHEMOKINE; CHEMOKINE RECEPTOR; CYTOKINE; DUFFY ANTIGEN RECEPTOR; ENZYME; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTEGRIN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; LAMIVUDINE; LIGAND; LYMPHOCYTE ANTIGEN RECEPTOR; MESSENGER RNA; POLYPEPTIDE; TRIPARTITE MOTIF PROTEIN 5; UNCLASSIFIED DRUG; VIRUS RNA; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CANDIDA ALBICANS; CATALYSIS; CELL ADHESION; CELL SPECIFICITY; CLINICAL TRIAL; COHORT ANALYSIS; CYTOMEGALOVIRUS; DENDRITIC CELL; DENGUE VIRUS; DISEASE COURSE; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG RESISTANCE; DRUG RESPONSE; EBOLA VIRUS; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE CONTROL; GENE FUNCTION; GENE THERAPY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HELICOBACTER PYLORI; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOREACTIVITY; INFECTION RATE; INFECTION RISK; INNATE IMMUNITY; KLEBSIELLA PNEUMONIAE; LEISHMANIA; LEISHMANIA PIFANOI; MAJOR HISTOCOMPATIBILITY COMPLEX; MYCOBACTERIUM TUBERCULOSIS; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PATHOGENESIS; POPULATION RISK; PRIORITY JOURNAL; REVIEW; SCHISTOSOMA MANSONI; SCREENING TEST; VIRUS ENTRY; VIRUS TRANSMISSION; WESTERN BLOTTING;

ACQUIRED IMMUNODEFICIENCY SYNDROME; DISEASE PROGRESSION; DISEASE SUSCEPTIBILITY; HIV INFECTIONS; HUMANS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 62449338922     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/j.1399-0039.2009.01220.x     Document Type: Review

References (50)

1. Visciano ML, Tuen M, Chen PD, Hioe CE. Antibodies to the CD4-binding site of HIV-1 gp120 suppress gp120-specific CD4 T cell response while enhancing antibody response. Infect Agent Cancer 2008 : 18 : 11.
2. + T cells to secrete CCR5 ligands and suppress HIV infection. Virology 2007 : 369 : 214 25.
3. Vasiliver-Shamis G, Tuen M, Wu T et al. HIV-1 envelope gp120 induces a stop signal and virological synapse formation in non-infected CD4 T cells. J Virol 2008 : 82 : 9445 57.
4. Telenti A, Goldstein DB. Genomics meets HIV. Nat Rev Microbiol 2006 : 4 : 9 18.
5. Winkler C, An P, Brien SJO. Patterns of ethnic diversity among the genes that influence AIDS. Hum Mol Genet 2004 : 13 : R9 R19.
6. Deeks SG, Walker BD. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 2007 : 27 : 406 16.
7. Baker BM, Block BL, Rothchild AC, Walker BD. Elite control of HIV infection: implications for vaccines and treatments. Expert Opin Biol Ther 2009 : 9 : 55 69.
8. Brass AL, Dykxhoorn DM, Benita Y et al. Identification of host proteins required for HIV infection through a functional genomic screen. Science 2008 : 319 : 921 6.
9. O'Brien SJ, Nelson GW. Human genes that limit AIDS. Nat Genet 2004 : 36 : 565 74.
10. Fellay J, Shianna KV, Ge D et al. A whole-genome association study of major determinants for host control of HIV-1. Science 2007 : 317 : 944 7.
11. Loeuillet C, Deutsch S, Cluffi A et al. In vitro whole-genome analysis identifies a susceptibility locus for HIV-1. PLoS Biol 2008 : 6 : e32. doi:10.1371/journal.pbio.0060032.
12. Smith MW, Dean M, Carrington M et al. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. Science 1997 : 277 : 959 65.
13. Kaur G, Singh P, Kumar N et al. Distribution of CCR2 polymorphism in HIV-1 infected and healthy subjects in North India. Int J Immunogenet 2007 : 34 : 153 6.
14. Ramana GV, Vasanthi A, Khaja M et al. Distribution of HIV-1 resistance-conferring polymorphic alleles SDF-1-3'A, CCR2-64I and CCR5-Delta32 in diverse populations of Andhra Pradesh, South India. J Genet 2001 : 80 : 137 40.
15. Louisirirotchanakul S, Liu H, Roongpisuthipong A et al. Genetic analysis of HIV-1 discordant couples in Thailand: association of CCR2 64I homozygosity with HIV-1 negative status. J Acquir Immune Defic Syndr 2002 : 29 : 314 5.
16. Gonzalez E, Bamshad M, Sato N et al. Race-specific HIV-1 disease-modifying effects associated with CCR5 haplotypes. Proc Natl Acad Sci U S A 1999 : 96 : 12004 9.
17. Liu R, Paxton WA, Choe S et al. Homozygous defects in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996 : 86 : 367 77.
18. Dean M, Carrington M, Winkler C et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 1996 : 273 : 1856 62.
19. Singh P, Kaur G, Sharma G, Mehra NK. Immunogenetic basis of HIV-1 infection, transmission and disease progression. Vaccine 2008 : 26 : 2966 80.
20. Martin MP, Dean M, Smith MW et al. Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science 1998 : 282 : 1907 11.
21. Nguyen L, Li M, Chaowanachan T et al. CCR5 promoter haplogroups associated with HIV-1 discordant progression in Thai injection drug users. AIDS 2004 : 18 : 1327 33.
22. Kostrikis LG, Neumann AU, Thomson B et al. A polymorphism in the regulatory region of the CC chemokine receptor 5 gene influences perinatal transmission of HIV 1 to African American infants. J Virol 1999 : 73 : 10264 71.
23. Kaur G, Singh P, Rapthap CC et al. Polymorphism in the CCR5 gene promoter and HIV-1 infection in North Indians. Hum Immunol 2007 : 68 : 454 61.
24. Modi WS, Lautenberger J, An P et al. Genetic variation in the CCL18-CCL3-CCL4 chemokine gene cluster influences HIV type 1 transmission and AIDS disease progression. Am J Hum Genet 2006 : 79 : 120 8.
25. Gonzalez E, Kulkarni H, Bolivar H et al. The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science 2005 : 307 : 1434 40.
26. Townson JR, Barcellos LF, Nibbs RJB. Gene copy number regulates the production of the human chemokine CCL3-L1. J Immunol 2002 : 32 : 3016 26.
27. Nakajima T, Ohtani H, Naruse T et al. Copy number variations of CCL3L1 and long-term prognosis of HIV-1 infection in asymptomatic HIV-infected Japanese with hemophilia. Immunogenetics 2007 : 59 : 793 8.
28. Nakajima T, Kaur G, Mehra N, Kimura A. HIV-1/AIDS susceptibility and copy number variation in CCL3L1, a gene encoding a natural ligand for HIV-1 co-receptor CCR5. Cytogenet Genome Res (in press).
29. Shao W, Tang J, Song W et al. CCL3L1 and CCL4L1: variable gene copy number in adolescents with and without HIV-1 infection. Genes Immun 2007 : 8 : 224 31.
30. Kulkarni H, Marconi VC, Agan BK et al. Role of CCL3L1-CCR5 genotypes in the epidemic spread of HIV-1 and evaluation of vaccine efficacy. PLoS ONE 2008 : 3 : e3671. doi:10.1371/journal.pone.0003671.
31. Ahuja SK, Kulkarni H, Catano G et al. CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1 infected individuals. Nat Med 2008 : 14 : 413 20.
32. Shalekoff S, Meddows-Taylor S, Schramm DB et al. Host CCL3L1 gene copy number in relation to HIV-1 specific CD4+ and CD8+ T cell responses and viral load in South African women. J Acquir Immune Defic Syndr 2008 : 48 : 245 54.
33. Liu H, Chao D, Nakayama EE et al. Polymorphism in RANTES chemokine promoter affects HIV-1 disease progression. Proc Natl Acad Sci U S A 1999 : 96 : 4581 5.
34. An P, Nelson GW, Wang L et al. Modulating influence on HIV/AIDS by interacting RANTES gene variants. Proc Natl Acad Sci U S A 2002 : 99 : 10002 7.
35. Rathore A, Chatterjee A, Sivarama P, Yamamoto N, Singhal PK, Dhole TN. Association of RANTES -403 G/A, -28 C/G and In1.1 T/C polymorphism with HIV-1 transmission and progression among North Indians. J Med Virol 2008 : 80 : 1133 41.
36. Winkler C, Modi W, Smith MW et al. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. Science 1998 : 279 : 389 93.
37. Ramamoorti N, Kumarvelu J, Shanmugasundaram GK, Rani K, Banerjea AC. 2001 High frequency of G to A transition mutation in the stromal cell derived factor-1 gene in India, a chemokine that blocks HIV-1 (X4) infection: multiple proteins bind to 3'-untranslated region of SDF-1 RNA. Genes Immun 2001 : 2 : 408 10.
38. Suresh P, Wanchu A, Sachdeva RK, Bhatnagar A. Gene polymorphisms in CCR5, CCR2, CX3CR1, SDF-1 and RANTES in exposed but uninfected partners of HIV-1 infected individuals in North India. J Clin Immunol 2006 : 26 : 476 84.
39. Richardson RM, Tokunaga K, Marjoram R, Sata T, Snyderman R. Interleukin-8-mediated heterologous receptor internalization provides resistance to HIV-1 infectivity. Role of signal strength and receptor desensitization. J Biol Chem 2003 : 278 : 15867 73.
40. Vasilescu A, Terashima Y, Enomoto M et al. A haplotype of the human CXCR1 gene protective against rapid disease progression in HIV-1+ patients. Proc Natl Acad Sci U S A 2007 : 104 : 3354 9.
41. He W, Neil S, Kulkarni H et al. Duffy antigen receptor for chemokines mediates trans-infection of HIV-1 from red blood cells to target cells and affects HIV-AIDS susceptibility. Cell Host Microbe 2008 : 4 : 52 62.
42. Boily-Larouche G, Zijenah LS, Mbizvo M, Ward BJ, Roger M. DC-SIGN and DC-SIGNR genetic diversity among different ethnic populations: potential implications for pathogen recognition and disease susceptibility. Hum Immunol 2007 : 68 : 523 30.
43. Martin MP, Lederman MM, Hutcheson HB et al. Association of DC-SIGN promoter polymorphism with increased risk for parenteral, but not mucosal, acquisition of human immunodeficiency virus type 1 infection. J Virol 2004 : 78 : 14053 6.
44. Zhang J, Webb DM. Rapid evolution of primate antiviral enzyme APOBEC3G. Hum Mol Genet 2004 : 13 : 1785 91.
45. Mulder LC, Harari A, Simon V. Cytidine deamination induced HIV-1 drug resistance. Proc Natl Acad Sci U S A 2008 : 105 : 5501 6.
46. Schrofelbauer B, Chen D, Landau NR. A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif). Proc Natl Acad Sci U S A 2004 : 101 : 3927 32.
47. Chiu YL, Soros VB, Kreisberg JF, Stopak K, Yonemoto W, Greene WC. Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells. Nature 2005 : 435 : 108 14.
48. Xu H, Svarovskaia ES, Barr R et al. A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion. Proc Natl Acad Sci U S A 2004 : 101 : 5652 7.
49. OhAinle M, Kerns JA, Li MM, Malik HS, Emerman M. Antiretroelement activity of APOBEC3H was lost twice in recent human evolution. Cell Host Microbe 2008 : 4 : 249 59.
50. van Manen D, Rits MA, Beugeling C, van Dort K, Schuitemaker H, Kootstra NA. The effect of Trim5 polymorphisms on the clinical course of HIV-1 infection. PLoS Pathog 2008 : 4 : e18.